Ghost Tree Capital’s NextCure NXTC Stock Holding History

Ghost Tree Capital’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-33,333	Closed	-$3.52M	–	52
2020 Q3	$3.52M	Buy	+33,333	New	+$4.1M	1.02%	31

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CPX

Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Ghost Tree Capital's NXTC Position: Q4 2020 in Review

Ghost Tree Capital sold out of NextCure (NXTC) in Q4 2020, closing a stake of 33,333 shares — an estimated $3.52M sold.

Ghost Tree Capital first reported a position in NXTC in Q3 2020 and held it in 1 quarter. The position peaked at $3.52M in Q3 2020. 83 funds tracked by Wall St. Rank hold NXTC as of Q4 2020.

Ghost Tree Capital reported no remaining NextCure position as of Q4 2020 after selling out during the quarter.
Ghost Tree Capital sold 33,333 NextCure shares in Q4 2020, an estimated $3.52M.
Ghost Tree Capital first reported a position in NextCure in Q3 2020 and held it in 1 quarter.
Ghost Tree Capital's NextCure position peaked at $3.52M in Q3 2020.
83 funds tracked by Wall St. Rank held NextCure as of Q4 2020.

Based on Ghost Tree Capital's 13F filing for Q4 2020, filed 16 Feb 2021.